Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.73 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6039255 | 0.90 | KDM4E (0.71) | KDM4EALDH1A1LMNAHPGDMAPT | |
| SCHEMBL6038771 | 0.90 | KDM4E (0.69) | KDM4EALDH1A1LMNAMAPTHSD17B10 | |
| SCHEMBL6039113 | 0.89 | KDM4E (0.58) | KDM4EALDH1A1LMNASMN1; SMN2MAPT | |
| SCHEMBL6038709 | 0.87 | KDM4E (0.56) | KDM4ENPC1ALDH1A1LMNAMAPT | |
| SCHEMBL6038871 | 0.86 | KDM4E (0.58) | KDM4EALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL6038981 | 0.85 | KDM4E (0.57) | KDM4EALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL6038684 | 0.84 | KDM4E (0.72) | KDM4EALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL6038447 | 0.83 | KDM4E (0.58) | KDM4EALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL6038874 | 0.81 | MEN1 (0.59) | KDM4EALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL6039009 | 0.80 | MEN1 (0.61) | KDM4EALDH1A1LMNAHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1541563-A1 | CCR4 ANTAGONIST AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | CCR4, CCR1, CCR9 | KDM4E 3561/4885NPC1 1760/4885ALDH1A1 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.